Brinter

Brinter is a bioprinting company that uses proprietary multi-material 3D bioprinting technology to manufacture medical-grade, biosynthetic implants intended to support tissue regeneration and healing. Its flagship product is a regenerative breast reconstruction implant aimed at post-mastectomy reconstruction and aesthetic revision applications. A second program covers regenerative orthopedic implants developed primarily for tendon and ligament repair, and the company states it is working with medical professionals and researchers on additional future implant categories. The company notes that its 3D bioprinted tissue implants are investigational devices that have not been approved for commercial use in any country and that described design properties and intended purposes remain subject to further validation.

Earlier in its history the company built and sold bioprinting hardware. Its modular 'Brinter 1' platform deposited cell-laden hydrogels for applications including oncological models and cancerous and cartilage microtissues, and supported interchangeable printheads such as the Pneuma Tool for low-to-medium viscosity bio-inks, the temperature-regulating Visco Heated Tool and the Granu Tool for granulate extrusion. Accompanying software converted MRI, X-ray or CT data into CAD models for printing soft tissue constructs used in drug evaluation and disease modelling. The machine was priced at €24,900. The company also sold bioprinting systems, modules and inks to medical, research and cosmetics customers.

A related operation, AM Technologies by Brinter, positions Brinter technology for advanced additive manufacturing services spanning process development, validation, manufacturing and scale-up, citing applications in predictive process engineering, pharmaceutical manufacturing, functional materials, bioelectronics, living materials, regenerative medicine and industrial additive manufacturing.

Founding story

According to the company, Brinter was founded in Finland in 2018 by serial technology founder Tom (Tomi) Alapaattikoski and Tomi Kalpio, an automotive manufacturing plant inventor, around the question of whether human tissue could be 3D bioprinted. The company cites science-fiction works including Blade Runner, The Fifth Element and Westworld as inspiration for its focus on technology that rebuilds the human body. Press coverage describes the company as a spin-off from the 3D printing bureau 3DTech Ltd, based in Turku, Finland.

Business model

Brinter's current focus is developing and commercializing proprietary regenerative implants for human tissue repair, which remain investigational devices pending regulatory approval. Historically the company sold bioprinting hardware, modular printheads, inks and accompanying software to research, medical and cosmetics customers, with its Brinter 1 system priced at €24,900. Through AM Technologies by Brinter it also offers engineering services across process development, validation, manufacturing and scaling of additive manufacturing applications.

Historically hardware, module and consumable (bio-ink) sales plus software to research and industry customers; the implant products are not yet approved for commercial sale in any country.

Traction

The company reports 10 patents, 8+ years of R&D, $4.5M of investment and $6.5M in grants. Reported users of its bioprinting technology have included Nanoform, VTT, the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, the University of Helsinki and the University of Eastern Finland, where the technology was used to 3D print neural matter for brain disease modelling. It has been a Wake Forest Institute for Regenerative Medicine partner since 2022 and an alumnus of Techstars (2024) and Plug and Play (2025).

Latest developments

The company states that as of 2026 it is approaching commercialization of a 3D bioprinted regenerative implant in the United States, with a regenerative breast reconstruction implant as its flagship product and regenerative orthopedic implants for tendon and ligament repair in development. Its leadership team is listed as CEO Tomi Alapaattikoski, COO Theo Arhio and Head of Manufacturing Tomi Kalpio, supported by a surgeon advisory board.